JNJ vs the Top Picks average
| Pillar | JNJ | Book avg | Diff |
|---|---|---|---|
| Quality | 0.78 | 0.84 | -0.06 |
| Growth | 0.70 | 0.87 | -0.17 |
| Value | 0.17 | 0.76 | -0.58 |
Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Analyst estimate revisions
| 30-day change | -4.1% |
|---|---|
| 90-day change | -3.2% |
| Forward EPS estimate | $12.31 |
Over the last 90 days, what analysts expect JNJ to earn is drifting lower (-3.2%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Johnson & Johnson (JNJ): score, valuation & FAQ
Johnson & Johnson (JNJ) is a Drug Manufacturers - General company that scores 45.7 out of 100 on the Bull Rankings quality-growth model — a below-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are FCF (A), while PEG (D) rate weaker. On valuation, JNJ sits about 67% above our discounted-cash-flow fair value — the current price implies roughly 21% annual free-cash-flow growth over the next decade.
Is JNJ a good stock to buy?
Bull Rankings scores JNJ 45.7 out of 100 on its quality-growth model, which is a below-average reading. That is driven by FCF (A). A score is a quantitative screen of Johnson & Johnson's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does JNJ score 45.7 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). JNJ earns its highest marks on FCF (A), and is held back by PEG (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is JNJ overvalued or undervalued?
Based on $273.04, JNJ sits about 67% above our discounted-cash-flow fair value — the current price implies roughly 21% annual free-cash-flow growth over the next decade. It trades at a 31.3x P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in JNJ?
Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 31x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.